Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw an upside of 4.05% to close Friday at $36.49 after adding $1.42 on the day. The 5-day average trading volume is 395,220 shares of the company’s common stock. It has gained $38.09 in the past week and touched a new high 1 time within the past 5 days. An average of 388,905 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 341,782.
XENE’s 1-month performance is -3.67% or -$2.56 on its low of $34.94 reached on 08/18/23. The company’s shares have touched a 52-week low of $31.79 and high of $43.75, with the stock’s rally to the 52-week high happening on 06/13/23. YTD, XENE has lost -7.46% or -$2.94 and has reached a new high 9 times. However, the current price is down -16.59% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
XENE stock investors last saw insider trading activity on Jun 01.PIMSTONE SIMON N. (Director) most recently sold 31,713 shares at $38.82 per share on Jun 01. This transaction cost the insider $1,231,247. Director, PIMSTONE SIMON N., sold 62,526 shares at a price of $38.70 on May 31. Then, on May 30, Director PIMSTONE SIMON N. sold 37,006 shares at a price of $39.28 per share. This transaction amounted to $1,453,672.
Valuation Metrics
XENE stock has a beta of 1.35. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 22496.09 while the price-to-book (PB) in the most recent quarter is 3.72.
Xenon Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 19.30, with the current ratio over the same period at 19.30. The trailing 12-month EBITDA margin is -1351.70%. The firm’s gross profit as reported stood at $138.58 million against revenue of $9.43 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 34.34% to -$47.46 million, while revenue of -$41.73 million was 12.07% off the previous quarter. Analysts expected XENE to announce -$0.7 per share in earnings in its latest quarter, but it posted -$0.72, representing a -2.90% surprise. EBITDA for the quarter stood at more than -$55.02 million. XENE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 38.44 million, with total debt at $11.51 million. Shareholders hold equity totaling $64.15 million.
Let’s look briefly at Xenon Pharmaceuticals Inc. (XENE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 47.09% to suggest the stock is trending Neutral, with historical volatility in this time period at 53.78%.
The stock’s 5-day moving average is $36.59, reflecting a -3.21% or -$1.21 change from its current price. XENE is currently trading -1.41% above its 20-day SMA, +5.95% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -12.41% and SMA200 by-0.22%.
Stochastic %K and %D was 26.05% and 37.32% and the average true range (ATR) pointed at 1.47. The RSI (14) points at 46.16%, while the 14-day stochastic is at 38.65% with the period’s ATR at 1.44. The stock’s 9-day MACD Oscillator is pointing at -0.64 and -0.87 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Xenon Pharmaceuticals Inc. (NASDAQ: XENE), Cantor Fitzgerald launched coverage with an Overweight rating. Analysts offering their rating for XENE stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate XENE as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 13 have offered a “buy” rating.
What is XENE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $46.00 and a high of $60.00, with their median price target at $52.00. Looking at these predictions, the average price target given by analysts is for Xenon Pharmaceuticals Inc. (XENE) stock is $52.69.
